Navigation Links
Bone Drug Lowers Risk of Breast Cancer Recurrence
Date:5/31/2008

Zometa, used to treat osteoporosis, showed no unanticipated side effects, researchers report

SATURDAY, May 31 (HealthDay News) -- A drug used to treat osteoporosis lowered the risk of breast cancer recurrence in premenopausal women with early breast cancer.

The Austrian researchers also found that women who took Zometa (zoledronic acid) had a 30 percent lower risk of the cancer spreading to the bone, with other benefits as well.

"We found not only an effect on bone metastases, which one might have anticipated, but also on local regional recurrence, distant bone metastases and contralateral breast cancer," said study author Dr. Michael Gnant, a professor of surgery at the Medical University of Vienna. "The indication is that zoledronic acid exerts a benefit through a variety of mechanisms which, all together, create a tumor-hostile environment..."

Gnant, who presented his findings this weekend at the American Society of Clinical Oncology annual meeting in Chicago, spoke at a Saturday news conference. The trial was partially supported by Novartis, which makes Zometa.

Earlier studies had indicated that Zometa can reduce bone loss occurring as a result of cancer treatment, and that it might also have an effect on the cancer itself.

For this trial, researchers randomized 1,803 patients to one of four arms: hormone therapies tamoxifen or Arimidex (anastrozole, an aromatase inhibitor), with or without Zometa.

Tamoxifen stops estrogen from reaching cancer cells while Arimidex interferes with actual production of estrogen. The hormone estrogen fuels breast cancer cells in estrogen-receptor positive tumors.

All patients were undergoing drug-induced ovarian suppression (to stop production of estrogen), had had surgery to remove the primary tumor, and had seen the cancer spread to 10 or fewer lymph nodes. Treatment lasted three years.

After a median follow-up of five years, either hormone therapy plus Zometa reduced the risk of relapse by 36 percent compared with hormone therapy alone. There were no unanticipated side effects, and the drugs were generally well-tolerated.

"The overall outcome of patients in this trial was excellent," Gnant said. "This is reassuring that patients with endocrine [hormone]-response disease, even in premenopause, can be safely treated with adjuvant chemotherapy. The benefit was seen in and outside the bone."

Although about 5 percent of participants had had chemotherapy before surgery to shrink the tumor, none received later chemo. In Europe, breast cancer patients are commonly treated with endocrine therapy alone," said Dr. Joanne Mortimer, vice chairwoman of medical oncology at City of Hope Cancer Center in Duarte, Calif. In the United States, some, but not all, women in this group are treated without chemotherapy.

"This is not a trial about hormones instead of chemo. It's about Zometa," Mortimer said. "We know that this drug improves bone health, but there is also some evidence that it may actually have an effect on cancer cells, and the fact that this was seen in this population is very exciting."

More information

The American Society of Clinical Oncology has more information on breast cancer.



SOURCES: Joanne Mortimer, vice chairwoman, medical oncology, City of Hope Cancer Center, Duarte, Calif.; May 31, 2008, news conference with Michael Gnant, M.D., professor, surgery, Medical University of Vienna, Austria; May 31, 2008, presentation, American Society of Clinical Oncology annual meeting, Chicago


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Brisk Walking Lowers Blood Pressure, Increases Fitness in Obese
2. Calpis AmealPeptide lowers blood pressure in 2 placebo-controlled trials
3. Data from Pooled Analyses Demonstrates Welchol, Combined with Metformin- or Sulfonylurea-Based Therapy, Significantly Lowers Blood Glucose in Adults with Type 2 Diabetes
4. Aspirin at Bedtime Lowers Blood Pressure
5. The Childrens Heart Foundation Teams Up With ProFlowers(R) to Raise Awareness and Funding for the Leading Birth Defect in America
6. 2-drug blood pressure therapy lowers cardiovascular risk
7. Hospital Testing for Drug-Resistant Infections Dramatically Lowers Mortality Rates and Costs
8. Galichia Heart Hospital Lowers Cost of Bypass to $10K
9. Aggressive Diabetes Therapy Lowers Death Risk, Study Finds
10. Major Community Health Organization Lowers TCO with Ericoms Alternative to Citrix
11. Anti-Inflammatory Drug Improves Glycemia, Lowers Inflammation in Obese, Young Adults
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... ... Bruton Memorial Library on June 21 due to a possible lice infestation, as reported by ... lice: the parasite’s ability to live away from a human host, and to infest common ... the event that lice have simply gotten out of control. , As lice are a ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, Dr. ... his M.D from the David Geffen School of Medicine at UCLA. He trained in ... to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he ...
(Date:6/25/2016)... Montreal, Canada (PRWEB) , ... June 25, 2016 , ... ... the pursuit of success. In terms of the latter, setting the bar too high ... low, risk more than just slow progress toward their goal. , Research from ...
(Date:6/24/2016)... ... 2016 , ... June 19, 2016 is World Sickle Cell Observance Day. In ... benefits of holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued ... Sickle Cell Disease (SCD) is a disorder of the red blood cells, which can ...
(Date:6/24/2016)... Fla. (PRWEB) , ... June 24, 2016 , ... Global ... Trend magazine’s 2016 Legal Elite. The attorneys chosen by their peers for this recognition ... Florida. , Seven Greenberg Traurig Shareholders received special honors as members of this year’s ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016 ... Market by Type (Standard Pen Needles, Safety Pen Needles), ... (Insulin, GLP-1, Growth Hormone), Mode of Purchase (Retail, Non-Retail) ... MarketsandMarkets, This report studies the market for the forecast ... to reach USD 2.81 Billion by 2021 from USD ...
(Date:6/24/2016)... 24, 2016  Arkis BioSciences, a leading innovator ... more durable cerebrospinal fluid treatments, today announced it ... funding is led by Innova Memphis, followed by ... private investors.  Arkis, new financing will accelerate the ... market release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... -- Any dentist who has made an implant supported denture ... of them do not even offer this as a viable ... costs involved. And those who ARE able to offer that ... cost that the majority of today,s patients would not be ... , founder of Dental Evolutions Inc. and inventor of Implanova ...
Breaking Medicine Technology: